Teaching faculty
Dr Maya H Buch is an Associate Professor and Honorary Consultant Rheumatologist; Section Head, Clinical Musculoskeletal Medicine and Deputy Director of the Leeds Institute of Rheumatic & Musculoskeletal Medicine, Chapel Allerton Hospital, University of Leeds, UK.
Having obtained her medical qualification from the University of Birmingham, UK, followed by internal medicine training, also in Birmingham, Dr Buch commenced specialist rheumatology training in Leeds. She completed a PhD and subsequently undertook a Clinical Research Fellowship at the University of Michigan Hospitals Scleroderma Program, Ann Arbor, USA, before completing specialist rheumatology training in Leeds as a clinical academic.
Dr Buch has extensive experience in immunotherapies in autoimmune disease. Her main research programme focuses on clinical trials in rheumatoid arthritis (RA) and biologic therapy stratification in RA underpinned by a ‘reverse translation’ approach: with clinical and biological investigation of biologic drug failure, refractory rheumatoid arthritis and prediction of treatment response, as well as evaluation of the wider immunomodulatory effect of biologic therapies on co-morbidity (particularly cardiovascular disease) in RA. She also maintains clinical and research activity in the management of systemic sclerosis.
She has been involved in several EULAR task force initiatives including the initial and recently updated EULAR recommendations on management of RA and was co-lead author on the updated consensus on rituximab in RA. She sits on the Arthritis Research UK Adult Inflammatory Arthritis Clinical Study Group Steering Committee, was Abstract Chair for EULAR 2014 and is current Chair of the Scientific programme, EULAR 2015.
Having obtained her medical qualification from the University of Birmingham, UK, followed by internal medicine training, also in Birmingham, Dr Buch commenced specialist rheumatology training in Leeds. She completed a PhD and subsequently undertook a Clinical Research Fellowship at the University of Michigan Hospitals Scleroderma Program, Ann Arbor, USA, before completing specialist rheumatology training in Leeds as a clinical academic.
Dr Buch has extensive experience in immunotherapies in autoimmune disease. Her main research programme focuses on clinical trials in rheumatoid arthritis (RA) and biologic therapy stratification in RA underpinned by a ‘reverse translation’ approach: with clinical and biological investigation of biologic drug failure, refractory rheumatoid arthritis and prediction of treatment response, as well as evaluation of the wider immunomodulatory effect of biologic therapies on co-morbidity (particularly cardiovascular disease) in RA. She also maintains clinical and research activity in the management of systemic sclerosis.
She has been involved in several EULAR task force initiatives including the initial and recently updated EULAR recommendations on management of RA and was co-lead author on the updated consensus on rituximab in RA. She sits on the Arthritis Research UK Adult Inflammatory Arthritis Clinical Study Group Steering Committee, was Abstract Chair for EULAR 2014 and is current Chair of the Scientific programme, EULAR 2015.